Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Apixaban Tablets

Approved

化学药品

Apixaban Tablets

BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD🇨🇳 National Medical Products Administration

Approval Date: Sep 27, 2022
Approval ID: 0d98893223e7c766
Company: BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD
Type: 化学药品

Approval Details

Approval Id: 0d98893223e7c766
Approval Number: 国药准字HJ20170236
Generic Name: 阿哌沙班片
Generic Name En: Apixaban Tablets
Trade Name: 艾乐妥
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 2.5mg
Reg Date: 2022-09-27
Expired Date: 2027-09-26
Company Name: BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD
Company Detail Path: /organization/bristol-myers-squibb-australia-pty-ltd

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Sep 27, 2022

Approval ID

0d98893223e7c766

Type

化学药品

Back to NMPA Approvals

艾乐妥 - NMPA Drug Approval Details